Suppressor tRNA Anticodon Mutation for Premature Stop Codon Readthrough
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively addressing premature stop codons in genes, which lead to truncated and nonfunctional proteins, causing various genetic disorders such as Dravet Syndrome.
Innovation Solution
Introducing an expression vector capable of expressing a tRNA with an anticodon that hybridizes to premature stop codons, allowing amino acid incorporation and extension of the protein sequence, thereby producing a functional gene product.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a premature stop codon is present in a gene, then protein synthesis terminates early producing a truncated protein, but the protein becomes nonfunctional or less functional
Solution Approach 1:
The patent introduces a suppressor tRNA as an intermediary molecule that mediates between the premature stop codon and the amino acid incorporation machinery. This tRNA contains a mutated anticodon that specifically recognizes and binds to the premature stop codon sequence, allowing the ribosome to continue translation and incorporate amino acids beyond the premature stop site, thereby restoring full-length functional protein production
Solution Approach 2:
The patent applies parameter changes by mutating the anticodon sequence of the tRNA to match the specific premature stop codon sequence. This parameter modification allows the tRNA to recognize and bind to the premature stop codon instead of causing termination, enabling readthrough and production of full-length protein
2Reliability
If current methods are used to address premature stop codons, then treatment options are limited, but effective treatment outcomes cannot be achieved
Solution Approach 1:
The patent segments the treatment approach by designing specific suppressor tRNAs tailored to individual premature stop codon mutations. Each tRNA is customized with an anticodon matching the specific mutant stop codon sequence, allowing targeted treatment of different nonsense mutations causing various genetic disorders including Dravet Syndrome
Solution Approach 2:
The patent establishes a universal therapeutic platform where suppressor tRNAs can be applied to treat multiple different genetic disorders caused by various premature stop codon mutations. The same general mechanism (suppressor tRNA delivery) can address different diseases such as Dravet Syndrome, cystic fibrosis, and other nonsense mutation-related disorders
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach increases the production of functional gene products, enhancing protein activity and improving treatment outcomes for disorders mediated by premature stop codons, including Dravet Syndrome.
Implementation Method 1
comprises an anticodon that hybridizes to the premature stop codon
Data Source
AI summary
Modified tRNAs can be used to express in a mammalian cell a functional gene product encoded by a gene containing a premature stop codon and/or to treat a disease mediated by a premature stop codon.